ArticleCommunications biology2025
ALKBH5 regulates intrauterine adhesion progression through m6A dependent FABP4 mRNA stabilization and serum lipid metabolism.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- 3D HucMSCs derived extracellular vesicles enhanced therapeutic efficacy in treating intrauterine adhesions via BECN1 delivery.Materials today. Bio · 2026Article
- The N6-Methyladenosine RNA Demethylase AlkB Homolog 5 (ALKBH5) in Metabolic Diseases: Molecular Mechanisms and Pharmacological Implications-A Review.Biomolecules · 2026Review
- Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Endometrial fibrosis is the main feature of intrauterine adhesion (IUA). The m6A methylation is involved in the process of fibrosis. However, the regulatory pathways involved in m6A methylation in endometrial fibrosis remain unclear. ALKBH5 is differentially low expressed in the endometrial tissues of IUA. Overexpression of ALKBH5 inhibits TGF-β1-induced fibrosis. In the in vivo experiment, ALKBH5 overexpression reduces the degree of endometrial fibrosis in rats. ALKBH5 regulates the m6A methylation level of FABP4 mRNA. FABP4 expression is inhibited by WT-ALKBH5, but not by catalytically inactive MUT-ALKBH5 (H204A). The m6A reader IGF2BP2 targets FABP4 and affects FABP4 mRNA stability. Inhibition of FABP4 decreases the expression of fibrosis-related markers (α-SMA, collagen I, collagen III, and Fibronectin). In addition, serum lipid metabolism is disordered in IUA rats, and ALKBH5 overexpression could partially reverse the levels of differential lipid metabolites. In conclusion, ALKBH5 is differentially low expressed in IUA. ALKBH5 signaling regulates endometrial fibrosis through FABP4 mRNA m6A methylation and lipid metabolism. This finding can provide theory support for the potential treatment strategy development of IUA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.